Clinical Trial Update: A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors [Phase 2]

View source ↗

Summary

A Phase 2 study of IBI363 in combination therapy for advanced solid tumors, including EGFR-mutant non-small cell lung cancer and platinum-resistant ovarian canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Ovarian Cancer

Drugs mentioned

• IBI363

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer | Phase 2 | Status: NOT_YET_RECRUITING